

- **Name:** Lajos Puztai, MD DPhil  
Professor of Medicine,
  - **Current Position & Affiliation:** Director of Breast Cancer Translational Research  
Co-Director of the Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine
  - **Country:** USA
- 

- **Educational Background:**

MD: Degree Semmelweis University School of Medicine, Budapest, Hungary  
D.Phil (PhD) degree: Wadham College, University of Oxford, Oxford, England

- **Professional Experience:**

2012- current Professor of Medicine (Medical Oncology), Yale University, School of Medicine, New Haven, CT  
1999-2012 Professor of Medicine, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

- **Professional Organizations:**

2017-current Chair, Breast Cancer Research Committee, The Southwest Oncology Group (SWOG),  
2018-current Member, ASCO Conquer Cancer Foundation Award Committee  
2020-current Member, ASCO Breast Cancer Biomarkers Guideline Panel  
2016-current Member, Board of Directors, The HOPE Foundation, SWOG  
2010-current Member, Scientific Advisory Board of the Breast Cancer research Foundation

- **Main Scientific Publications:**

I have published over 300 peer reviewed manuscripts, a complete list of publications can be found at: <https://www.ncbi.nlm.nih.gov/pubmed/?term=Lajos+Puztai>. My total citations are 46,328 and my H-index is 96 (<https://scholar.google.com/citations?user=IHogWesAAAAJ&hl=en&oi=ao> ).

a. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippin J, Andre F, Simon R, Puztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. **J Natl Cancer Inst.** 2011;103(3):264-72. PubMed PMID: 21191116.

- b. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Puztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. **J Clin Oncol.** 2006;24(26):4236-44. PubMed PMID: 16896004.
- c. Hatzis C, Puztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. **JAMA.** 2011;305(18):1873-81. PubMed PMID: 21558518.
- a. Karn T, Jiang T, Hatzis C, Sanger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Puztai L: Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. **JAMA Oncol.** 2017 Jul 27; PMID: 28750120
- b. Safonov A, Jiang T, Bianchini G, Gyorffy B, Karn T, Hatzis C, Puztai L: Immune gene expression is associated with genomic aberrations in breast cancer. **Cancer Res.** 2017 Apr 20; 2017 Apr 20. PMID: 28428277
- c. Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pena L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Puztai L. Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial. **Ann Oncol.** 2017, 28 (1): 128-135
- d. Frampton A., Fichtenholtz A., Otto G., Wang K., Downing S., He J., Schnall-Levin M., White J., Sanford E., An P., Sun J., Brennan K., Juhn F., Brennan K., Iwanik K., Maillet A., Buell J., White E., Zhao M., Balasubramanian S., Terzic S., Richards T., Banning V., Garcia L., Mahoney K., Zwirko Z., Donahue A., Beltran H., Mosquera J., Rubin M., Dogan S., Hedvat C., Berger M., Puztai L., Lechner M., Boshoff C., Jarosz M., Vietz C., Parker A., Miller V., Ross J., Curran J., Cronin M., Stephens P., Lipson D. and Yelensky R.. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. **Nature Biotechnology** 2013. Nov; 31 (11):1023-31
- e. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Puztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. **J Clin Oncol.** 2010;28(28):4316-23. PubMed PMID: 20805453.